Vaccine prophylaxis of pneumococcal infection: what a therapist needs to know (overview of the symposium within the XVI National Congress of Internists)


DOI: https://dx.doi.org/10.18565/therapy.2021.10.132-137

Malyavin A.G.

A.I. Yevdokimov Moscow State University of Medicine and Dentistry of the Ministry of Healthcare of Russia
Abstract. This review considers current trends in the field of vaccine prophylaxis of pneumococcal infection, presented by experts at the XVI National Congress of Internists. Much attention is paid to assessing its relevance for Russian patients.
Keywords: pneumococcal infection, community-acquired pneumonia, vaccination
Read entire article

Literature


  1. Welte T., Torres A., Nathwani D. Clinical and economic burden of community-acquired pneumonia among adults in Europe. Thorax. 2012; 67(1): 71–79. doi: 10.1136/thx.2009.129502.

  2. Lode H.M. Managing community-acquired pneumonia: a European perspective. Respir Med. 2007; 101(9): 1864–73. doi: 10.1016/j.rmed.2007.04.008.

  3. Биличенко Т.Н., Аргунова А.Н., Антонова О.А. с соавт. Частота пневмококковой пневмонии у взрослых больных терапевтических стационаров на трех территориях Российской Федерации. Пульмонология. 2013; 4: 29–36. [Bilichenko T.N., Argunova A.N., Antonova O.A. et al. Pneumococcal pneumonia frequency in therapeutic adult inpatients at three Russian regions. Pulmonologiya = Pulmonology. 2013; 4: 29–36 (In Russ.)]. https://doi.org/10.18093/0869-0189-2013-0-4-29-36.

  4. Cilloniz C., Amaro R., Torres A. Pneumococcal vaccination. Curr Opin Infect Dis. 2016; 29(2): 187–96. doi: 10.1097/QCO.0000000000000246.

  5. WHO: The top 10 causes of death. Available at: https://www.who.int/en/news-room/fact-sheets/detail/the-top-10-causes-of-death (date of access – 01.12.2021).

  6. Shea K.M., Edelsberg J., Weycker D. et al. Rates of pneumococcal disease in adults with chronic medical conditions. Open Forum Infect Dis. 2014; 1(1): ofu024. doi: 10.1093/ofid/ofu024.

  7. ECDC. Annual epidemiological report 2018. Invasive pneumococcal disease. Stockholm: ECDC. 2020. Available at: https://www.ecdc.europa.eu/sites/default/files/documents/AER_for_2018_IPD.pdf (date of access – 01.12.2021).

  8. О состоянии санитарно-эпидемиологического благополучия населения в Российской Федерации в 2019 году: государственный доклад. М.: Федеральная служба по надзору в сфере защиты прав потребителей и благополучия человека. 2020; 299 с. [On the state of sanitary and epidemiological well-being of the population in the Russian Federation in 2019: State report. Moscow: Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing. 2020; 299 pp. (In Russ.)].

  9. Yang Y., Xu F., Shi L.Y. et al. Efficacy and significance of various scores for pneumonia severity in the management of patients with community-acquired pneumonia in China. Chin Med J (Engl). 2012; 125(4): 639–45.

  10. Поляков Д.С., Фомин И.В., Валикулова Ф.Ю. соавт. Оценка влияния внебольничной пневмонии на краткосрочный и долгосрочный прогноз у больного с декомпенсацией хронической сердечной недостаточности. Терапевтический архив. 2016, 9: 17–22. [Polyakov D.S., Fomin I.V., Valikulova F.Yu. et al. Evaluation of the impact of community-acquired pneumonia on short-term and long-term prognosis in a patient with chronic decompensated heart failure. Terapevticheskiy arkhiv = Therapeutic Archive. 2016, 9: 17–22 (In Russ.)]. https://doi.org/10.17116/terarkh201688917-22.

  11. Luna C.M., Palma I., Niederman M.S. et al. The impact of age and comorbidities on the mortality of patients of different age groups admitted with community-acquired pneumonia. Ann Am Thorac Soc. 2016; 13(9): 1519–26. doi: 10.1513/AnnalsATS.201512-848OC.

  12. Musher D.M., Rueda A.M., Kaka A.S., Mapara S.M. The association between pneumococcal pneumonia and acute cardiac events. Clin Infect Dis. 2007; 45(2): 158–65. doi: 10.1086/518849.

  13. Kornum J.B., Thomsen R.W., Riis A. et al. Type 2 diabetes and pneumonia outcomes: a population-based cohort study. Diabetes Care. 2007; 30(9): 2251–57. doi: 10.2337/dc06-2417.

  14. GOLD. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2021 Report. Available at: https://goldcopd.org/2021-gold-reports (date of access – 01.12.2021).

  15. GINA. Global strategy for asthma management and prevention. 2020 update. Available at: https://ginasthma.org/wp-content/uploads/2020/04/GINA-2020-full-report_-final-_wms.pdf (date of access – 01.12.2021).

  16. American Diabetes Association. 4. Comprehensive medical evaluation and assessment of comorbidities: Standards of medical care in diabetes-2019. Diabetes Care. 2019; 42(Suppl 1): S34–S45. doi: 10.2337/dc19-S004.

  17. Об утверждении национального календаря профилактических прививок и календаря профилактических прививок по эпидемическим показаниям: приказ Министерства здравоохранения Российской Федерации (Минздрава России) от 21.03.2014 № 125н. [On the approval of the National calendar of preventive vaccinations and the Calendar of preventive vaccinations for epidemic indications: Order of the Ministry of Healthcare of Russia dated March 21, 2014 No. 125n. (In Russ.)].

  18. Приказ Министерства здравоохранения Российской Федерации от 19.02.2019 № 69н «О внесении изменения в приложение № 2 к приказу Министерства здравоохранения Российской Федерации от 21 марта 2014 г. № 125н “Об утверждении национального календаря профилактических прививок и календаря профилактических прививок по эпидемическим показаниям”». [Order of the Ministry of Healthcare of Russia of February 19, 2019 No. 69n «On amendments to appendix No. 2 to the Order of the Ministry of Healthcare of Russia No. 125n of March 21, 2014 «On approval of the National calendar of preventive vaccinations and the Calendar of preventive vaccinations for epidemic indications» (In Russ.)].

  19. Инструкция по медицинскому применению лекарственного препарата Пневмовакс® 23 (Вакцина пневмококковая, поливалентная). РУ: ЛП-003441. Доступ: https://grls.rosminzdrav.ru (дата обращения – 01.12.2021). [Instructions for the medical use of the medicinal product Pneumovax®. Registration certificate: ЛП-003441. State Register of Medicines of the Ministry of Health of Russia. Available at: https://grls.rosminzdrav.ru/ (date of access – 01.12.2021) (In Russ.)].

  20. Falkenhorst G., Remschmidt C., Harder T. et al. Effectiveness of the 23-valent pneumococcal polysaccharide vaccine (PPV23) against pneumococcal disease in the elderly: Systematic review and meta-analysis. PLoS One. 2017; 12(1): e0169368. doi: 10.1371/journal.pone.0169368.

  21. Ochoa-Gondar O., Vila-Corcoles A., Rodriguez-Blanco T. et al. Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against community-acquired pneumonia in the general population aged ≥ 60 years: 3 years of follow-up in the CAPAMIS study. Clin Infect Dis. 2014; 58(7): 909–17. doi:10.1093/cid/ciu002.

  22. Maruyama T., Taguchi O., Niederman M.S. et al. Efficacy of 23-valent pneumococcal vaccine in preventing pneumonia and improving survival in nursing home residents: Double blind, randomised and placebo controlled trial. BMJ. 2010; 340: c1004. doi: 10.1136/bmj.c1004.

  23. Клинические рекомендации. Внебольничная пневмония у взрослых. Российское респираторное общество, Межрегиональная ассоциация по клинической микробиологии и антимикробной химиотерапии. 2021. Рубрикатор клинических рекомендаций Минздрава России. Доступ: https://cr.minzdrav.gov.ru/schema/654_1 (дата обращения – 01.12.2021). [Clinical guidelines. Community-acquired pneumonia in adults. Russian Respiratory Society, Interregional Association for Clinical Microbiology and Antimicrobial Chemotherapy. 2021. Rubricator of clinical guidelines of the Ministry of Healthcare of Russia. Available at: https://cr.minzdrav.gov.ru/schema/654_1 (date of access – 01.12.2021) (In Russ.)].

  24. Hung I.F., Leung A.Y., Chu D.W. et al. Prevention of acute myocardial infarction and stroke among elderly persons by dual pneumococcal and influenza vaccination: a prospective cohort study. Clin Infect Dis. 2010; 51(9): 1007–16. doi: 10.1086/656587.

  25. Брико Н.И., Коршунов В.А., Васильева И.А., Воробьева А.Д. Вакцинация против пневмококковой инфекции взрослых групп риска. Туберкулез и болезни легких. 2020; 5: 15–23. [Briko N.I., Korshunov V.A., Vasilyeva I.A., Vorobieva A.D. Vaccination against pneumococcal infection in adults from risk groups. Tuberkulez i bolezni legkikh = Tuberculosis and Lung Disease. 2020; 5: 15–23 (In Russ.)]. https://doi.org/10.21292/2075-1230-2020-98-5-15-23 .

  26. Subesinghe S., Rutherford A.I., Byng-Maddick R. et al. Recurrent serious infections in patients with rheumatoid arthritis-results from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford). 2018; 57(4): 651–55. doi: 10.1093/rheumatology/kex469.

  27. Xu Z., Xu P., Fan W. et al. Risk of infection in patients with spondyloarthritis and ankylosing spondylitis receiving antitumor necrosis factor therapy: A meta-analysis of randomized controlled trials. Exp Ther Med. 2017; 14(4): 3491–500. doi: 10.3892/etm.2017.5003.

  28. Furer V., Rondaan C., Heijstek M.W. et al. 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2020; 79(1): 39–52. doi: 10.1136/annrheumdis-2019-215882.

  29. Salinas G.F., De Rycke L., Barendregt B. et al. Anti-TNF treatment blocks the induction of T cell-dependent humoral responses. Ann Rheum Dis. 2013; 72(6): 1037–43. doi: 10.1136/annrheumdis-2011-201270.

  30. Grabar S., Groh M., Bahuaud M. et al.; VACCILUP study group. Pneumococcal vaccination in patients with systemic lupus erythematosus: A multicenter placebo-controlled randomized double-blind study. Vaccine. 2017; 35(37): 4877–85. doi: 10.1016/j.vaccine.2017.07.094.

  31. Тарасова Г.М., Белов Б.С., Черкасова М.В. с соавт. Иммуногенность, переносимость и клиническая эффективность 23-валентной полисахаридной пневмококковой вакцины у больных системной красной волчанкой. Антибиотики и химиотерапия. 2020; 5–6: 35–40. [Tarasova G.M., Belov B.S., Cherkasova M.V. et al. Immunogenicity, tolerability, and clinical effectiveness of 23-valent polysaccharide pneumococcal vaccine in patients with systemic lupus erythematosus. Antibiotiki i khimioterapiya = Antibiotics and Chemotherapy. 2020; 5–6: 35–40 (In Russ.)]. https://doi.org/10.37489/0235-2990-2020-65-5-6-35-40.


About the Autors

Andrei G. Malyavin, MD, professor, professor of the Department of phthisiology and pulmonology of the faculty of general medicine, A.I. Yevdokimov Moscow State University of Medicine and Dentistry of the Ministry of Healthcare of Russia. Address: 107150, Moscow, 39/2 Losinoostrovskaya Str. E-mail: maliavin@mail.ru. ORCID: 0000-0002-6128-5914


Similar Articles

Back to Content

Бионика Медиа